一种基于巨细胞病毒的疫苗单剂量接种后可对致死性埃博拉病毒攻击提供持久保护。
A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose.
作者信息
Tsuda Yoshimi, Parkins Christopher J, Caposio Patrizia, Feldmann Friederike, Botto Sara, Ball Susan, Messaoudi Ilhem, Cicin-Sain Luka, Feldmann Heinz, Jarvis Michael A
机构信息
Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Vaccine and Gene Therapy Institute, Oregon Health & Sciences University, Portland, Oregon, USA.
出版信息
Vaccine. 2015 May 5;33(19):2261-2266. doi: 10.1016/j.vaccine.2015.03.029. Epub 2015 Mar 25.
Abstract
Ebola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.
摘要
埃博拉病毒（扎伊尔埃博拉病毒；EBOV）是一种高度致命的出血热疾病病毒，最近分别在西非多个国家和刚果民主共和国引发了两次独立的2014年疫情。在此，我们表明，一种基于巨细胞病毒（CMV）的疫苗在单次接种后能提供持久的针对埃博拉病毒的保护性免疫。这项研究对人类埃博拉病毒疫苗接种以及开发一种针对野生非洲大猩猩体内这些病毒的“传播性”疫苗具有启示意义。
相似文献
1
A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose.
Vaccine. 2015 May 5;33(19):2261-2266. doi: 10.1016/j.vaccine.2015.03.029. Epub 2015 Mar 25.
2
A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus.
PLoS Negl Trop Dis. 2011 Aug;5(8):e1275. doi: 10.1371/journal.pntd.0001275. Epub 2011 Aug 9.
3
Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
J Infect Dis. 2015 Oct 1;212 Suppl 2(Suppl 2):S443-51. doi: 10.1093/infdis/jiv316. Epub 2015 Jun 24.
4
DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.
Hum Vaccin Immunother. 2017 Dec 2;13(12):3010-3019. doi: 10.1080/21645515.2017.1382780. Epub 2017 Nov 14.
5
Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
J Virol. 2006 Mar;80(6):2738-46. doi: 10.1128/JVI.80.6.2738-2746.2006.
6
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
Nature. 2015 Apr 30;520(7549):688-691. doi: 10.1038/nature14428. Epub 2015 Apr 8.
7
Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge.
EBioMedicine. 2019 Nov;49:223-231. doi: 10.1016/j.ebiom.2019.09.055. Epub 2019 Oct 17.
8
Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
mBio. 2019 May 28;10(3):e00597-19. doi: 10.1128/mBio.00597-19.
9
Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses.
Emerg Infect Dis. 2015 Feb;21(2):305-7. doi: 10.3201/eid2102.141649.
10
Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.
PLoS One. 2015 Sep 30;10(9):e0137786. doi: 10.1371/journal.pone.0137786. eCollection 2015.
引用本文的文献
1
Can Humanized Immune System Mouse and Rat Models Accelerate the Development of Cytomegalovirus-Based Vaccines Against Infectious Diseases and Cancers?
Int J Mol Sci. 2025 Mar 27;26(7):3082. doi: 10.3390/ijms26073082.
2
Molecular cloning and host range analysis of three cytomegaloviruses from .
J Virol. 2025 May 20;99(5):e0214724. doi: 10.1128/jvi.02147-24. Epub 2025 Apr 9.
3
Heightened innate immune state induced by viral vector leads to enhanced response to challenge and prolongs malaria vaccine protection.
iScience. 2024 Nov 26;27(12):111468. doi: 10.1016/j.isci.2024.111468. eCollection 2024 Dec 20.
4
Recombinant transmissible vaccines will be intrinsically contained despite the ability to superinfect.
Expert Rev Vaccines. 2024 Jan-Dec;23(1):294-302. doi: 10.1080/14760584.2024.2320845. Epub 2024 Feb 28.
5
The Quest for Immunity: Exploring Human Herpesviruses as Vaccine Vectors.
Int J Mol Sci. 2023 Nov 9;24(22):16112. doi: 10.3390/ijms242216112.
6
Exploring the Potential of Cytomegalovirus-Based Vectors: A Review.
Viruses. 2023 Oct 2;15(10):2043. doi: 10.3390/v15102043.
7
Isolation and genome sequencing of cytomegaloviruses from Natal multimammate mice ().
J Gen Virol. 2023 Aug;104(8). doi: 10.1099/jgv.0.001873.
8
An attenuated herpesvirus vectored vaccine candidate induces T-cell responses against highly conserved porcine reproductive and respiratory syndrome virus M and NSP5 proteins that are unable to control infection.
Front Immunol. 2023 Aug 3;14:1201973. doi: 10.3389/fimmu.2023.1201973. eCollection 2023.
9
MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination.
Cell Mol Immunol. 2022 Feb;19(2):234-244. doi: 10.1038/s41423-021-00814-5. Epub 2022 Jan 7.
10
Production- and Purification-Relevant Properties of Human and Murine Cytomegalovirus.
Viruses. 2021 Dec 10;13(12):2481. doi: 10.3390/v13122481.
本文引用的文献
1
Investigating the zoonotic origin of the West African Ebola epidemic.
EMBO Mol Med. 2015 Jan;7(1):17-23. doi: 10.15252/emmm.201404792.
2
Vaccinating captive chimpanzees to save wild chimpanzees.
Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8873-6. doi: 10.1073/pnas.1316902111. Epub 2014 May 27.
3
The 2014 Ebola virus disease outbreak in West Africa.
J Gen Virol. 2014 Aug;95(Pt 8):1619-1624. doi: 10.1099/vir.0.067199-0. Epub 2014 May 2.
4
Absence of frequent herpesvirus transmission in a nonhuman primate predator-prey system in the wild.
J Virol. 2013 Oct;87(19):10651-9. doi: 10.1128/JVI.01104-13. Epub 2013 Jul 24.
5
Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates.
Sci Transl Med. 2012 Oct 31;4(158):158ra146. doi: 10.1126/scitranslmed.3004582.
6
A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.
J Immunother. 2012 Jun;35(5):390-9. doi: 10.1097/CJI.0b013e3182585d50.
7
Regulation of Antigen-Experienced T Cells: Lessons from the Quintessential Memory Marker CD44.
Front Immunol. 2012 Feb 27;3:23. doi: 10.3389/fimmu.2012.00023. eCollection 2012.
8
A single-dose cytomegalovirus-based vaccine encoding tetanus toxin fragment C induces sustained levels of protective tetanus toxin antibodies in mice.
Vaccine. 2012 Apr 26;30(20):3047-52. doi: 10.1016/j.vaccine.2012.02.043. Epub 2012 Mar 10.
9
Consequences of non-intervention for infectious disease in African great apes.
PLoS One. 2011;6(12):e29030. doi: 10.1371/journal.pone.0029030. Epub 2011 Dec 22.
10
A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus.
PLoS Negl Trop Dis. 2011 Aug;5(8):e1275. doi: 10.1371/journal.pntd.0001275. Epub 2011 Aug 9.
Zotero 插件